Navigation Links
ViroPharma Announces Discontinuation of HCV-796 Development
Date:4/16/2008

EXTON, Pa., April 16 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) announced today that ViroPharma and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), have jointly discontinued the development of HCV-796 due to the previously announced safety issue that emerged in the ongoing Phase 2 trial in patients with hepatitis C.

"Clearly, this is a disappointing outcome for patients suffering from this difficult disease," commented Vincent Milano, ViroPharma's president and chief executive officer. "Significant activities were undertaken to determine a clear path forward for HCV-796; however, the risk associated with potential hepatotoxicity ultimately posed too high of a hurdle to merit further development."

The companies will ensure that patients enrolled in the ongoing Phase 2 study will continue to receive the current standard of care. ViroPharma also announced that ViroPharma and Wyeth do not expect to continue to collaborate on future development of hepatitis C treatment candidates.

About ViroPharma Incorporated

ViroPharma Incorporated is committed to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...lif.,Nov.25/PRNewswire-FirstCall/--Abaxis,Inc.(Nas...int-of-carebloodanalysissystems,announcedtodaythat...lpresentatthe21stAnnualPiperJaffrayHealthCareConfe...ferencewillbeheldattheNewYorkPalaceHotelinNewYorkC...facturesandmarketsportablebloodanalysissystemsforu...
(Date:11/25/2009)....25/PRNewswire-FirstCall/--NuVasive,Inc.(Nasdaq: N...uctsforminimallydisruptivesurgicaltreatmentsforthe...nMonday,November30,2009,at5:30p.m.ET/2:30p.m.PT.Th...eimbursementfortheCompany,sproductsandwillincludec...swersession.Thedial-innumbersare1-877-407-4018ford...
(Date:11/25/2009)...25/PRNewswire/--Reportlinker.comannouncesthatanewm..., IntranasalDrugDelivery-USMarketTrends&Analy...al-Drug-Delivery---US-Market-Trends--Analysis.html...inganexpansionoftherapeuticapplicationsfromthedeli...ryofsystemictherapeuticdrugs.Thefutureofthetechnol...
Breaking Medicine Technology:NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr Robert Garnick as Head of Regulatory Affairs 5551 1Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr Robert Garnick as Head of Regulatory Affairs 5551 2Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr Robert Garnick as Head of Regulatory Affairs 5551 3Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr Robert Garnick as Head of Regulatory Affairs 5551 4Lifeclinic to Engage People Over 50 in Utilizing Technology and Wellness at AARP 2009 Event and Expo 59738 1Lifeclinic to Engage People Over 50 in Utilizing Technology and Wellness at AARP 2009 Event and Expo 59738 2Lifeclinic to Engage People Over 50 in Utilizing Technology and Wellness at AARP 2009 Event and Expo 59738 3Household Insecticides May Be Linked to Autoimmune Diseases 59735 1Household Insecticides May Be Linked to Autoimmune Diseases 59735 2Household Insecticides May Be Linked to Autoimmune Diseases 59735 3
...urnal Blood found 92 percent reduction in ... Conn., Aug. 20 Patients with a rare,blood disord...n the,incidence of life-threatening blood clots (t...culizumab), according to an analysis of clinical s...rnal of the American Society of,Hematology. Solir...
...1 Genaera,Corporation (Nasdaq: GENR ) today repo...initiated a multi-dose, Phase 2a clinical trial wi...ukin-9 (IL-9) in adults with,mild, persistent asth...is,designed to evaluate the safety and tolerabilit... the second Phase 2a study currently underway with...
Other Medicine Technology:PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 2PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 3PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 4PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 5PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 6PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 7PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 8Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program 2Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program 3Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program 4
(Date:11/26/2009)...o more letters from the North Pole, Textsanta.net ...s from Santa , North Pole...al efficiencies at the North Pole Santa Claus has ... over the globe informed of his Christmas progress...earch department have identified a large and growi...
(Date:11/25/2009)...PRNewswire-USNewswire/--Whenmostpeopleheartheacron...lsogivepatientsthehelptheyneed.TMJstandsfortheTemp...contacts/connectswithyourskull(temporalbone). ,...narepainwithchewing,clickingorpoppingofthejaw.Butm...ding:headaches,fatigue,sleepdisturbances,irritabil...
(Date:11/25/2009)...v.25/PRNewswire/--Thanksgivingmealswillbedelivered...ngBeachareathankstoFaithInAction/VolunteerActionfo...divisionofSCANHealthPlan.Formorethan17yearstheseor...erwarmThanksgivingmealstoseniorsinneedinLongBeach,...roundingcities. ,, "Ourwarmholidaymealsaredeliv...
(Date:11/25/2009)...sticular cancer who were treated with cisplatin-ba...luding neurological side effects and Raynaud-like ...otherapy, according to a new study published onlin...er Institute . , Marianne Brydy, M.D., of the De...l, in Bergen, Norway, and colleagues conducted a c...
(Date:11/25/2009)...fight rheumatoid arthritis, could help newly diagn...Y, Nov. 25 (HealthDay News) -- A drug commonly use...rthritis now also shows some promise in helping pa...The drug, rituximab (Rituxan), helped patients kee... the disease had destroyed some of their pancreati...
Breaking Medicine News(10 mins):Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2Health News:SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors 2Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3
...ts at the Ohio State University have discovered a ...ainst the invasion of the HIV/AIDS virus. //It was...f injured DNA also destroy the DNA of the HIV viru...this discovery might lead to newer treatments targ...
...ts in Canada has said that choosing and eating the...erapy in lowering the cholesterol level//. Da...y of Toronto studied people who ate a diet high in... The participants, including 66 women and me...
...een proposed by the Ohio-based Cleveland Clinic, t...is summer, the services which would benefit Canadi...or medical treatment. The Cleveland clinic houses ...addition to information on health care options ava...
...ar study was conducted by the psychiatrist Dr Char... was backed by the National Institutes of Health//...fect of treating depression using drugs and psycho...onger periods, perhaps even for life, in patients ...
...epartment of New South Wales has conducted a study... serious impact on the user's physical health// . ...al health conditions. Cannabis abuse can lead to c... Wales Health Minister John Hatzistergos will open...
...ers at Yale shed new light on the mechanism of ner...a molecular "motor" protein, myosin-II, according ...Biology. As nerve cells develop or attempt to re...er to direct advance of the nerve cells and it has...
Other Medicine News:Health News:Satellite Clinic To Be Set Up in Toronto By Ohio-Based Cleveland Clinic 2Health News:Drugs Are Effective In Treating Depression and Preventing Recurrence 2Health News:A New Focus For The Mechanism Of Nerve Growth 2
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
Medicine Products: